x
Investment Opportunities

IPO Calendar

Companies release their IPO details at unpredictable times. That’s why we update this IPO calendar daily to give you the most up-to-date information available. To start, let’s look at this week’s IPOs.

This Week’s IPOs

Monday 10/26/20

  • NA

Tuesday 10/27/20

  • NA

Wednesday 10/28/20

Thursday 10/29/10

  • AmeriHome (NYSE: AHM)
  • Allegro Microsystems (Nasdaq: ALGM)
  • GBS (Nasdaq: GBS)
  • Galecto (Nasdaq: GLTO)
  • Caliber Home Loans (NYSE: HOMS)
  • Leslie’s (Nasdaq: LESL)
  • Mavenir (Nasdaq: MVNR)

Friday 10/30/20

  • Atea Pharmaceuticals (Nasdaq: AVIR)
  • G Medical Innovations (Nasdaq: GMVD)
  • Inhibikase Therapeutics (Nasdaq: IKT)
  • Lufax (NYSE: LU)
  • SQZ Biotechnologies (NYSE: SQZ)

Upcoming IPOs

If you’re interested in IPO investing, check out our Top Recent IPOs. And if you’re looking for the latest investment opportunities, you’re in the right place! Sign up for our free Investment U e-letter to receive daily tips and research from our experts. Whether you’re a beginner or an experienced investor, there’s something for everyone.

To learn more about the companies going public this week, you can find company information below.

Company Information

Biodesix (Nasdaq: BDSX)

Price Range: $17-$19
Offer Shares: 4,166,667

Biodesix’s prospectus states…

” We are a leading data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary artificial intelligence (AI) platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. By combining a technology agnostic approach with a holistic view of the patient’s disease state, we believe our solutions provide physicians with greater insights to help personalize their patient’s care and meaningfully improve disease detection, evaluation, and treatment. Our unique approach to precision medicine provides timely and actionable clinical information, which we believe improves overall patient outcomes and lowers the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. In addition to our diagnostic tests, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.”

Gatos Silver (NYSE: GATO)

Price Range: $7-$9
Offer Price: 18,750,000

Gatos Silver’s prospectus states…

“We are a U.S.-based precious metals production, development and exploration company with the objective of becoming a premier silver producer. We are currently focused on the production and continued development of the Cerro Los Gatos Mine and the further exploration and development of the Los Gatos District.”

MediaAlpha (NYSE: MAX)

Price Range: $18-$20
Offer Shares: 9,250,000

MediaAlpha’s prospectus states…

“Our mission is to help insurance carriers and distributors target and acquire customers more efficiently and at greater scale through technology and data science. Our technology platform brings leading insurance carriers and high-intent consumers together through a real-time, transparent, and results-driven ecosystem. We believe we are the largest online customer acquisition channel in our core verticals of property & casualty insurance, health insurance, and life insurance, supporting over $1 billion in Transaction Value across our platform over the last two years.”

Root (Nasdaq: ROOT)

Price Range: $22-$25
Offer Shares: 24,164,516

Root’s prospectus states…

“Root is a technology company revolutionizing personal insurance with a pricing model based upon fairness and a modern customer experience. We have built a company that recognizes each individual is unique and puts customers in control, rewarding them for their actions. For centuries, traditional insurance companies have grouped people into risk pools and long relied on the ‘law of large numbers’ to produce acceptable pricing on an aggregate basis. Fairness at the individual level has been largely ignored. Root is different—we use technology to measure risk based on individual performance, prioritizing fairness to the customer. The way we design and deliver insurance is not a simple tweak to the traditional insurance model—we are fundamentally reinventing insurance through technology, data science and a maniacal focus on the customer.”

AmeriHome (NYSE: AHM)

Price Range: $16-$18
Offer Shares: 14,705,882

AmeriHome’s prospectus states…

“We are a leading U.S. residential mortgage producer and servicer focused on driving profitable growth across market environments. We were founded in 2013 and designed to optimize operational and financial excellence, instilling a business strategy and culture we refer to as the “AmeriHome Way,” as detailed below. We have created a flexible and scalable platform with a modern purpose-built infrastructure, advanced data and analytics capabilities, all leveraging our management team’s collective experience to achieve what we believe is a highly efficient cost structure to target profitability in all market environments. This has led to strong growth and performance, evidenced by 21 consecutive quarters of profitability while growing our production volume 187.4% from 2015 to LTM Q2 2020, positioning us as the third largest correspondent producer.”

Allegro Microsystems (Nasdaq: ALGM)

Price Range: $12-$14
Offer Shares: 25,000,000

Allegro Microsystems’ prospectus states…

“Allegro MicroSystems is a leading global designer, developer, fabless manufacturer and marketer of sensor ICs and application-specific analog power ICs enabling the most important emerging technologies in the automotive and industrial markets. We are a leading supplier of power ICs, and according to Omdia, we are the number one supplier of magnetic sensor ICs driven by our market leadership in the automotive market. Our products are foundational to automotive and industrial electronic systems. Our sensor ICs enable our customers to precisely measure motion, speed, position and current, while our power ICs include high-temperature and high-voltage capable motor driver, power management and LED driver ICs. Our recently acquired photonics portfolio provides eye-safe distance measurement and 3D imaging solutions. We believe that our technology expertise combined with our deep applications knowledge and strong customer relationships enable us to develop solutions that provide more value to customers than typical ICs. Compared to a typical IC, our solutions are more highly integrated, add intelligence and sophistication for complex applications and are easier for customers to use.”

GBS (Nasdaq: GBS)

Price Range: $16-$18
Offer Shares: 9,806,471

GBS’ prospectus states…

“GBS is developing and commercializing a range of Biosensor based Point of Care (“POCT”) diagnostic tests that are developed in the modalities of clinical chemistry, immunology, tumor markers, allergens and endocrinology. Due to the nature of our platform technology (see figure below), we are able to quickly adapt to this rapidly evolving environment. Given the COVID-19 pandemic, the superior analytical characteristics of the biosensor technology and the advanced development stage, the company decided to expedite a collaboration with the Wyss Institute for Biologically Inspired Engineering at Harvard University (Wyss) in order to develop a more accurate and real time SARS-CoV-2 test for diagnostic, point-of-care screening and pre-vaccination screening.”

Galecto (Nasdaq: GLTO)

Price Range: $14-$16
Offer Shares: 5,666,667

Galecto’s prospectus states…

“We are a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Our initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, which play key roles in regulating fibrosis. We believe our product candidates are distinct from the current generation of antifibrotic agents and have the potential to significantly improve patients’ clinical outcomes and enhance their quality of life.”

Caliber Home Loans (NYSE: HOMS)

Price Range: $14-$16
Offer Shares: 23,000,000

Caliber Home Loans’ prospectus states…

“We are a proven leader in the U.S. mortgage market with a uniquely diversified, customer-centric, purchase-focused platform. We deliberately focus on the purchase market and are the second largest independent mortgage originator based on purchase volume since 2016, according to IMF. Guided by analytics and data, we have leveraged our robust platform to build impressive scale across our highly complementary channels. As a result, for the year ended December 31, 2019, we are the only player with a top 10 market position across all three channels tracked by IMF – retail, wholesale, and correspondent.”

Leslie’s (Nasdaq: LESL)

Price Range: $14-$16
Offer Shares: 40,000,000

Leslie’s prospectus states…

“We are the largest and most trusted direct-to-consumer brand in the nearly $11 billion United States pool and spa care industry, serving residential, professional, and commercial consumers. Founded in 1963, we are the only direct-to-consumer pool and spa care brand with national scale, operating an integrated marketing and distribution ecosystem powered by a physical network of 934 branded locations and a robust digital platform. We command a market-leading share of nearly 15% of residential aftermarket product spend, which represents an increase of approximately 500 basis points since 2010, our physical network is larger than the sum of our twenty largest competitors, and our digital sales are estimated to be greater than five times as large as that of our largest digital competitor. We offer an extensive assortment of professional-grade products, the majority of which are exclusive to Leslie’s, as well as certified installation and repair services, all of which are essential to the ongoing maintenance of pools and spas.”

Mavenir (Nasdaq: MVNR)

Price Range: $20-$24
Offer Shares: 12,500,000

Mavenir’s prospectus states…

“We provide software to drive the digital transformation of mobile networks. Our suite of cloud-native software applications delivers the critical network functionality that allows Wireless Service Providers to meet the needs of their enterprise and consumer customers. These software solutions are deeply embedded in the Wireless Service Provider networks to securely deliver and operate complex, mission-critical mobile services such as voice, messaging, video and connectivity that helps them to unlock new revenue opportunities. We are at the forefront of disruption in the mobile network infrastructure industry enabling networks to become more agile, flexible and scalable while reducing total cost of ownership (“TCO”). We believe that we are the only U.S. headquartered company with end-to-end, cloud-native, 5G capabilities.”

Atea Pharmaceuticals (Nasdaq: AVIR)

Price Range: $22-$24
Offer Shares: 11,000,000

Atea Pharmaceuticals’ prospectus states…

“We are a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Leveraging our deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, we have built a proprietary purine nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, we are focused on the development of orally available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, the virus that causes COVID-19, hepatitis C virus, or HCV, dengue virus, and respiratory syncytial virus, or RSV.”

G Medical Innovations Holdings (Nasdaq: GMVD)

Price Range: $5-$7
Offer Shares: 5,000,000

G Medical Innovations’ prospectus states…

“We are an early commercial stage healthcare company engaged in the development of next generation mobile health (or mHealth) and telemedicine solutions and monitoring service platforms. We believe we are at the forefront of the digital health revolution in developing the next generation mobile technologies and services that are designed to empower consumers, patients and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes.”

Inhibikase Therapeutics (Nasdaq: IKT)

Price Range: $10-$12
Offer Shares: 2,272,727

Inhibikase Therapeutics’ prospectus states…

“We are a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease, or PD, and related disorders that arise inside and outside of the brain. We filed two Investigational New Drug, or IND, applications with the U.S. Food and Drug Administration, or FDA, in the first quarter of 2019 for our lead asset candidate, IkT-148009. One IND is for the treatment of Parkinson’s Disease, while the second is for treatment of gastrointestinal, or GI, complications that arise as early symptoms of PD in patients. We initiated clinical development of IkT-148009 for the treatment of PD in 2019. First dosing of patients for treatment of PD is expected to commence shortly after the conclusion of this offering. Clinical development of IkT-148009 for the GI complications in PD patients will cross-reference the first human study of IkT-148009 for the treatment of PD.”

Lufax Holdings (NYSE: LU)

Price Range: $11.50-$13.50
Offer Shares: 175,000,000

Lufax Holdings’ prospectus states…

“We are a leading technology-empowered personal financial services platform in China. Our mission is to make retail borrowing and wealth management easier, safer and more efficient. We primarily address the large unmet demand for personal lending among small business owners as well as salaried workers in China, and we provide tailor-made wealth management solutions to China’s fast growing middle class and affluent population. As of June 30, 2020, our total balance of retail credit facilitated reached RMB519.4 billion (US$73.5 billion), and the total client assets generated through our online wealth management platform reached RMB374.7 billion (US$53.0 billion), ranking us number two and number three, respectively, among non-traditional financial service providers in China such as fintech companies, online-only TechFin companies and online lending platforms, according to Oliver Wyman.”

SQZ Biotechnologies (NYSE: SQZ)

Price Range: $16-$18
Offer Shares: 4,411,765

SQZ Biotechnologies’ prospectus states…

“We are a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. We use our proprietary technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. This technology allows us to create a broad pipeline of product candidates for different diseases. We believe our Cell Squeeze technology has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients. Our potential benefits include accelerated timelines with production time under 24 hours, compared to four to six weeks for other existing cell therapies, improved patient experience by eliminating the need for pre-conditioning or lengthy hospital stays, and broadened therapeutic impact. Our goal is to use the SQZ approach to establish a new paradigm for cell therapies.”

To learn more about upcoming IPOs and investing, don’t forget to sign up our free e-letter below. It’s packed with useful insight from investing experts.


Articles by
Related Articles